Physician profile
Eric Goldberg
NPI 1679524946
$208,037.58
in general payments reported to CMS, 2019-2025
36 companies · $118K in 2025
The $118K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,183 · 2020: $1,386 · 2021: $2,055 · 2022: $7,018 · 2023: $39K · 2024: $37K · 2025: $118K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $123K · Honoraria: $34K · Travel and Lodging: $19K · Food and Beverage: $13K · Consulting Fee: $5,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,680.00 |
| Honoraria | $33,925.00 |
| Travel and Lodging | $19,127.66 |
| Food and Beverage | $13,382.55 |
| Consulting Fee | $5,280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $112,233.16 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82,156.84 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $3,438.01 | 2019-2022 | |
| Mdd US Operations, LLC | $2,693.35 | 2025 | Qelbree |
| Abbvie INC. | $1,308.87 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $747.81 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $669.22 | 2023-2025 | Auvelity |
| Lundbeck LLC | $420.99 | 2019-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $403.51 | 2021-2025 | |
| Novo Nordisk INC | $391.08 | 2021-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $371.24 | 2021-2025 | Tezspire |
| Idorsia Pharmaceuticals US INC | $353.65 | 2022-2025 | Quviviq, Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $313.33 | 2019-2023 | Trintellix |
| Boston Scientific Corporation | $294.08 | 2024-2025 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $285.85 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $227.92 | 2019-2025 | Austedo Xr, Uzedy |
| Eisai INC. | $215.37 | 2020-2022 | |
| Allergan, INC. | $179.61 | 2019-2020 | |
| Neos Therapeutics, Lp | $170.10 | 2019-2023 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $151.28 | 2025 | Fanapt, Hetlioz |
| Corium, LLC | $144.95 | 2022-2025 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $117.93 | 2024 | Cobenfy |
| Alkermes, INC. | $98.30 | 2023-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $81.36 | 2021-2023 | Jornay Pm |
| Indivior INC. | $76.62 | 2020-2022 | |
| Tris Pharma INC | $65.60 | 2019-2023 | Dyanavel Xr |
| Almatica Pharma LLC | $62.17 | 2023-2024 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $50.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $42.66 | 2020-2023 | Verquvo, Belsomra |
| Avadel Cns Pharmaceuticals, LLC | $33.40 | 2025 | Lumryz |
| Alfasigma USA, INC. | $29.61 | 2021 | |
| Neurocrine Biosciences, INC. | $28.08 | 2021 | |
| Grifols USA, LLC | $21.74 | 2023 | Prolastin-C Liquid |
| Shire North American Group INC | $21.43 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.